Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis / Desempenho diagnóstico do VEGF-D para linfangioleiomiomatose: meta-análise

ABSTRACT Objective: VEGF-D is a potential biomarker for lymphangioleiomyomatosis (LAM); however, its diagnostic performance has yet to be systematically studied. Methods: We searched PubMed, EMBASE, Scopus, Web of Science, and Cochrane Library to identify primary studies on VEGF-D in relation to the diagnosis of LAM. The quality of the studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Summary estimates of diagnostic accuracy were pooled using a bivariate random effects model. Subgroup and sensitivity analyses were performed to explore possible heterogeneity. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was applied to rate the quality of evidence and indicate the strength of recommendations. Results: Ten studies involving 945 patients were of high risk in quality, as assessed using the QUADAS-2. The pooled diagnostic parameters were indicated as follows: sensitivity = 0.82 (95% CI, 0.71-0.90); specificity = 0.98 (95% CI, 0.94-0.99); and diagnostic OR = 197 (95% CI, 66-587). The AUC of summary ROC analysis was 0.98. The subgroup and sensitivity analyses revealed that the overall performance was not substantially affected by the composition of the control group, prespecified cutoff value, the country of origin, or different cutoff values (p > 0.05 for all). A strong recommendation for serum VEGF-D determination to aid in the diagnosis of LAM was made according to the GRADE. Conclusions: VEGF-D seems to have great potential implications for the diagnosis of LAM in clinical practice due to its excellent specificity and suboptimal sensitivity.

RESUMO Objetivo: O VEGF-D é um potencial biomarcador para linfangioleiomiomatose (LAM); entretanto, seu desempenho diagnóstico ainda não foi sistematicamente estudado. Métodos: Foram realizadas buscas nos bancos de dados PubMed, EMBASE, Scopus, Web of Science e Cochrane Library para identificar estudos primários sobre o VEGF-D com relação ao diagnóstico de LAM. A qualidade dos estudos foi avaliada por meio da ferramenta Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). As estimativas sumárias de acurácia diagnóstica foram combinadas utilizando um modelo bivariado de efeitos aleatórios. Análises de subgrupo e de sensibilidade foram realizadas para explorar possíveis heterogeneidades. O sistema Grading of Recommendations Assessment, Development, and Evaluation (GRADE) foi aplicado para avaliar a qualidade das evidências e indicar a força das recomendações. Resultados: Dez estudos envolvendo 945 pacientes eram de alto risco em qualidade, segundo a ferramenta QUADAS-2. Os parâmetros diagnósticos combinados foram indicados da seguinte forma: sensibilidade = 0,82 (IC95%: 0,71-0,90); especificidade = 0,98 (IC95%: 0,94-0,99); e OR diagnóstica = 197 (IC95%: 66-587). A ASC da análise summary ROC foi de 0,98. As análises de subgrupo e de sensibilidade revelaram que o desempenho global não foi substancialmente afetado pela composição do grupo controle, valor de corte pré-especificado, país de origem ou diferentes valores de corte (p > 0,05 para todos). Uma forte recomendação para a dosagem de VEGF-D sérico para auxiliar no diagnóstico de LAM foi feita de acordo com o sistema GRADE. Conclusões: O VEGF-D parece ter grandes implicações potenciais para o diagnóstico de LAM na prática clínica em virtude da excelente especificidade e sensibilidade subótima.

Sarcoma de Kaposi tipo linfangiomatoso: comunicación de un caso / 9 LYMPHANGIOMATOUS KAPOSI'S SARCOMA: CASE REPORT

El sarcoma de Kaposi linfangiomatoso es una variante clínica rara del sarcoma de Kaposi. Tiene la característica de presentarse como cavidades con contenido líquido que muchas veces se confunden con enfermedades ampollares de la piel. Presentamos un paciente masculino con antecedente de infección por VIH asociado a sarcoma de Kaposi clásico, diseminado a nivel pulmonar, gastrointestinal y cutáneo. Tras dos ciclos de quimioterapia mejoró el compromiso sistémico, pero comenzó con ampollas en ambos muslos, por lo que junto con estudios clínicos y estudios complementarios se llegó al diagnóstico de sarcoma de Kaposi linfangiomatoso.

Lymphangiomatous Kaposi's sarcoma is a rare clinical variant of Kaposi's sarcoma. It has the characteristic of appearing as cavities with liquid content that are often confused with blistering skin diseases. We present a male patient with a history of HIV infection associated with classic Kaposi's sarcoma, disseminated to the pulmonary, gastrointestinal and skin levels. After two cycles of chemotherapy, the systemic involvement improved but she began with blisters on both thighs, from which, together with clinical studies and complementary studies, a diagnosis of lymphangiomatous Kaposi's sarcoma was reached.

Linfangioleiomiomatosis pulmonar / Pulmonary lymphangioleiomyomatosis

Introducción: La linfangioleiomiomatosis pulmonar constituye un desafío, tanto en su manejo diagnóstico como en la atención de sus complicaciones. Es una enfermedad rara que se caracteriza por la proliferación del músculo liso alrededor de las estructuras bronco-vasculares, linfáticos y en el intersticio pulmonar, unido a la dilatación quística de los espacios aéreos terminales. Objetivo: Describir la evolución clínica y el tratamiento de un paciente con linfangioleiomiomatosis pulmonar. Presentación de caso: Se presenta un caso de linfangioleiomiomatosis pulmonar que desde el punto de vista clínico se manifestó por neumotórax a repetición. Se llegó a diagnóstico definitivo mediante la realización de una biopsia de pulmón. Desarrollo: La linfangioleiomiomatosis es una entidad rara que afecta fundamentalmente a mujeres en edad fértil y que se caracteriza por la presencia de un patrón quístico difuso. Su prevalencia e incidencia es desconocida. Conclusiones: Se puede concluir que la presencia de neumotórax espontáneo o recidivante en una mujer en edad fértil, o embarazada, debe sospecharse linfangioleiomiomatosis(AU)

Introduction: Pulmonary lymphangioleiomyomatosis constitutes a challenge, both in its diagnostic management and in the care of complications. It is a rare disease characterized by the proliferation of smooth muscle around the bronchovascular and lymphatic structures and in the pulmonary interstitium, together with cystic dilation of the terminal air spaces. Objective: To describe a diagnosed case of pulmonary lymphangioleiomyomatosis. Case report: A case of pulmonary lymphangioleiomyomatosis is reported, which was clinically showed as recurrent pneumothorax. A definitive diagnosis was reached by performing a lung biopsy. Discussion: Lymphangioleiomyomatosis is a rare entity that mainly affects women of childbearing age and is characterized by the presence of a diffuse cystic pattern. Its prevalence and incidence is unknown. Conclusions: It can be concluded that the presence of spontaneous or recurrent pneumothorax in a woman of childbearing age, or pregnant, should be suspected lymphangioleiomyomatosis(AU)

Neumotórax espontaneo en paciente gestante / Spontaneous Pneumothorax in a Pregnant Woman

RESUMEN Introducción: El neumotórax es una de las enfermedades pleurales más frecuentes en la práctica médica, siendo excepcional su asociación con el embarazo, existiendo pocos casos reportados en la literatura mundial. La linfangioleiomiomatosis es una enfermedad multisistémica poco frecuente, que afecta predominante al sexo femenino en edad fértil y puede verse exacerbada por el embarazo. Objetivo: Realizar el reporte de un caso y la revisión del tema que permitan un diagnóstico precoz y una conducta de forma temprana. Caso clínico: Paciente gestante de 15 semanas, de 36 años de edad, con antecedentes de salud anterior, que debuta súbitamente con disnea a los medianos esfuerzos, tos, dolor torácico y neumotórax derecho espontáneo, recurrente en su evolución y posteriormente bilateral. Su curso fue tórpido requiriendo tratamiento en Unidad de Cuidados Intensivos por fallo respiratorio agudo, falleciendo luego de 3 meses del inicio del cuadro. Se le realizó, Radiografía de tórax: patrón reticular de tipo panal de abejas, tomografía de tórax: imágenes quísticas múltiples en todo parénquima pulmonar de predominio basal. Biopsia pulmonar compatible con linfangioleiomiomatosis. Conclusiones: La aparición de disnea súbita, dolor pleurítico y neumotórax en una gestante, deben ser siempre suficientes para tener en cuenta la presencia de una linfangioleiomiomatosis. Su inespecificidad sintomática inicial se traduce en un diagnóstico tardío, lo que empobrece su pronóstico(AU)

ABSTRACT Introduction: Pneumothorax is one of the pleural diseases most frequent in medical practice. Its association with pregnancy is essential. Few cases are reported in worldwide medical literature. Lymphangioleiomyomatosis is a rare multisystem disease that predominantly affects individuals of the female sex and at fertile age; it can be aggravated by pregnancy. Objective: To present a case report and a topic review that allow early diagnosis and early management. Clinical case: A 15-week-pregnant patient aged 36 years and with a previous health history suddenly presented dyspnea for average efforts, cough, chest pain, and spontaneous right pneumothorax, recurrent in its evolution and, later, bilateral. Its evolution was slow, a reason why it required intensive care for acute respiratory failure. The patient died three months after the onset of symptoms. The patient was performed chest x-ray, which showed honeycomb-type reticular pattern; and chest tomography, which showed multiple cystic images throughout pulmonary parenchyma, predominantly at baseline. Lung biopsy consistent with lymphangioleiomyomatosis was performed. Conclusions: Onset of sudden dyspnea, pleuritic pain and pneumothorax in a pregnant woman should always be sufficiently indicative of lymphangioleiomyomatosis. Its initial symptomatic non-specificity is determined by late diagnosis, which impoverishes prognosis(AU)

Recurrence of retroperitoneal localized perivascular epithelioid cell tumor two years after initial diagnosis: case report

ABSTRACT CONTEXT: Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Adjuvant radiotherapy and/or chemotherapy are administered according to the patient's clinical characteristics. CASE REPORT: A 42-year-old female patient was operated to treat a retroperitoneal mass. The diagnosis was established as PEComa with benign behavior. Two years after the diagnosis, chest and abdominal computed tomography scans showed intra-abdominal recurrence and lymphangioleiomyomatosis in the lung. Treatment with everolimus was started. The disease stabilized in the third month of treatment, according to the response evaluation criteria in solid tumors. CONCLUSION: PEComas are tumors with unpredictable behavior. Therefore, these patients require long-term follow-up, even in cases of correct diagnosis and benign PEComa.

Linfangioleiomiomatosis pulmonar, una rara enfermedad pulmonar: presentación de un caso clínico / Pulmonary lymphangioleiomyomatosis, a rare lung disease: presentation of a clinical case

Introducción: La linfangioleiomiomatosis Pulmonar (LAM) es una rara y progresiva enfermedad; caracterizada por proliferación excesiva de células musculares lisas a partir de vasos linfáticos, sanguíneos y vías aéreas. En conjunto al anormal crecimiento celular descrito, se aprecia degeneración quística difusa del parénquima pulmonar, lo que puede reflejarse desde cuadros completamente asintomáticos hasta el deterioro severo del intercambio gaseoso con insuficiencia respiratoria fulminante. Descripción del caso: Paciente femenino de 41 años de edad, con cuadro clínico consistente en tos seca ocasional, asociada a dolor leve de características pleuríticas en 'puntada de costado ' derecha. Ante la no mejoría clínica, se indica estudio imagenológico donde se demuestra neumotorax espontáneo derecho. En estudio tomográfico se aprecian además lesiones pulmonares quísticas. El estudio anátomo-patológico demuestra cambios estructurales que se reportan compatibles con LAM. Conclusión: Dada la simplicidad de los síntomas con que la LAM puede debutar, su confirmación diagnóstica se genera en fases avanzadas de la enfermedad, cuando el daño pulmonar importante conlleva a la aparición de factores clínicos con mayor repercusión sobre el estado general de los pacientes por lo que la realización de estudios imagenológicos tempranos gana vital importancia.

Introduction: Pulmonary lymphangioleiomyomatosis (LAM) is a rare and progressive disease; characterized by airway, lymphatic and blood vessels-smooth muscle cells excessive proliferation. Added to the abnormal cell growth, parenchymal cystic degeneration is present, which can be reflected initially as a asymptomatic course and can progress to severe gaseous exchange deterioration and fulminating respiratory insufficiency. Case description: A 41-year-old female patient with a clinical course consisting of occasional dry cough, associated with mild pleuritic pain on the right side of thorax. As no improvement was achieved, thoracic imaging study was performed, where a right pneumothorax was found. Tomography images showed multiple lung cystic lesions. Anatomopathological study reports structural changes compatible with LAM. Conclusion: Given the simplicity of the symptoms that LAM can debut with, its diagnostic confirmation is generated in advanced stages of the disease, when the important pulmonary damage leads to the appearance of clinical factors with greater impact on the general state of patients so early thoracic imaging studies gain vital importance.

Caso Clínico: Linfangioleiomiomatosis en una Paciente Joven con Síndrome de Bourneville

INTRODUCCIÓN: El síndrome de Bourneville o esclerosis tuberosa es una alteración innata del desarrollo que se transmite de forma autosómica dominante, es causada por mutación en los genes TSC1 y TSC2. Se presenta en 1 de cada 6 000 habitantes; se considera una forma rara de facomatosis susceptible de originar tumores benignos en diversas zonas del cuerpo, entre los que se cita: angiomiolipomas renales, tumores del sistema nervioso, retina, corazón, piel y linfangioleiomiomatosis pulmonar; siendo la última una patología pulmonar quística, progresiva, que afecta a las mujeres en edad fértil y puede ser potencialmente mortal. CASO CLÍNICO: Se trata de una paciente de sexo femenino de 23 años de edad, mestiza, con antecedentes de esclerosis tuberosa, hipotiroidismo y nefrectomía izquierda por angiomiolipoma; que presentó un neumotórax espontáneo secundario a linfangioleiomiomatosis pulmonar. EVOLUCIÓN: En base a los antecedentes patológicos, cuadro clínico y estudios de imagen se diagnosticó de linfangioleiomiomatosis pulmonar. Se realizó una pleurodesis y se inició tratamiento con Sirolimus; la respuesta fue satisfactoria, se mantuvieron controles médicos periódicos evaluando la posibilidad de trasplante pulmonar a futuro. CONCLUSIÓN: El neumotórax espontáneo en una mujer joven con esclerosis tuberosa se asocia a linfangioleiomiomatosis pulmonar; en la actualidad esta patología es manejada con Sirolimus, los resultados han sido favorables en la función pulmonar y calidad de vida del paciente; el trasplante pulmonar sigue siendo el tratamiento de elección en la enfermedad avanzada.(au)

BACKGROUND: Bourneville syndrome or tuberous sclerosis is an innate development alteration transmitted by autosomal dominant inheritance. It is caused by TSC1 and TSC2 gene mutations and occurs in 1 of every 6 000 people. It is considered a rare form of phacomatosis that can cause multiple benign tumors including renal angiomyolipomas and tumors of the central nervous system, retina, heart and skin; pulmonary lymphangioleiomyomatosis can be part of the clinical presentation, affects women of childbearing age and can be life-threatening. CASE REPORT: 23 year-old female patient with history of tuberous sclerosis, hypothyroidism and left nephrectomy for angiomyolipoma, who presented a spontaneous pneumothorax secondary to pulmonary lymphangioleiomyomatosis. EVOLUTION: Based on the history, clinical picture and imaging studies; the diagnosis of pulmonary lymphangioleiomyomatosis was made. A pleurodesis was performed and a treatment with Sirolimus was started; the response was satisfactory, periodic controls were maintained evaluating the possibility of lung transplant in the future. CONCLUSION: Spontaneous pneumothorax in a young woman with tuberous sclerosis is associated with pulmonary lymphangioleiomyomatosis. Currently this pathology is managed with Sirolimus, the results have been favorable , improving pulmonary function and quality of life; lung transplantation remains the treatment of choice in advanced disease.(au)

Complejo linfangioleiomiomatosis-esclerosis tuberosa, ¿contraindicación para el trasplante pulmonar? Presentación de un caso / Lymphangioleiomyomatosis-Tuberous Sclerosis Complex. Contraindication For Lung Transplantation? A Case Report

El complejo linfangioleiomiomatosis (LAM)-esclerosis tuberosa (ET) es una enfermedad rara, con compromiso multisistémico que afecta principalmente pulmón y cerebro. Se presenta el caso de una paciente de 25 años con LAM pulmonar que ingresa a la institución para protocolo de trasplante pulmonar. Durante los estudios de extensión se documenta compromiso extrapulmonar sistémico del complejo LAM-ET. A partir de este caso, se realizó una revisión de la literatura de las manifestaciones radiológicas sistémicas de la enfermedad y las recomendaciones de diagnóstico y manejo de estos pacientes; en especial, las indicaciones y contraindicaciones del trasplante pulmonar.

The lymphangioleiomyomatosis (LAM) - Tuberous Sclerosis (TS) Complex is a rare disease with multisystem involvement affecting mainly lung and brain. We present the case of a 25-year-old female patient with pulmonary LAM. During the work-up studies for the lung transplantation protocol, the systemic extrapulmonary involvement of the LAM-TS complex is documented. From this case, a literature review of the systemic radiological manifestations of the disease and of the diagnosis and management recommendations of these patients was made. Special focus was made on the indications and contraindications of lung transplantation.

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations / Uso de sirolimo no tratamento de linfangioleiomiomatose: resposta favorável em pacientes com diferentes manifestações extrapulmonares

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare disease that is currently considered a low-grade neoplasm with metastatic potential and variable progression. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patients, especially those with extrapulmonary manifestations. The objective of the present study was to describe a case series of four patients with LAM in Brazil who showed significant improvement, particularly in their extrapulmonary manifestations, after treatment with sirolimus (at 1-4 mg/day). METHODS: We describe four cases of LAM patients with different extrapulmonary manifestations who were treated with sirolimus. RESULTS: After treatment with sirolimus for 12 months, one patient presented resolution of severe chylothorax; one had a significant reduction in renal angiomyolipoma volume; and one showed significant regression of retroperitoneal lymphangioleiomyomas and abdominal lymph node enlargement. After treatment with sirolimus for 6 months, the remaining patient had a significant reduction in the volume of a massive retroperitoneal lymphangioleiomyoma. CONCLUSIONS: Our findings confirm that mTOR inhibitors are beneficial for patients with LAM, especially those with extrapulmonary manifestations, such as renal angiomyolipoma, lymphangioleiomyomas, and chylous effusions. However, certain aspects, such as the optimal dose, duration of treatment, and long-term adverse effects, have yet to be sufficiently clarified for mTOR inhibitors to be incorporated into LAM management protocols. .

OBJETIVO: A linfangioleiomiomatose (LAM) é uma doença rara que é atualmente considerada uma neoplasia de baixo grau com potencial metastático e evolução variável. Os inibidores de mammalian target of rapamycin (mTOR), como o sirolimo e o everolimo, recentemente se tornaram uma opção para o tratamento de pacientes com LAM, especialmente daqueles com manifestações extrapulmonares. O objetivo deste estudo foi descrever quatro casos de pacientes com LAM no Brasil que apresentaram melhora, especialmente das manifestações extrapulmonares, após tratamento com sirolimo (em doses de 1-4 mg/dia). MÉTODOS: Descrevemos quatro casos de pacientes com LAM e diferentes manifestações extrapulmonares tratados com sirolimo. RESULTADOS: Após o tratamento com sirolimo por 12 meses, um paciente apresentou resolução do quilotórax de difícil manejo, um paciente teve redução significativa do volume do angiomiolipoma renal, e uma paciente apresentou regressão importante de linfangioleiomiomas retroperitoneais e linfonodomegalias abdominais. Após tratamento com sirolimo por 6 meses, um paciente apresentou redução significativa de volumoso linfangioleiomioma retroperitoneal. CONCLUSÕES: Nossos achados confirmam que os inibidores de mTOR são benéficos para pacientes com LAM, especialmente para aqueles com manifestações extrapulmonares, tais como angiomiolipomas renais, linfangioleiomiomas e derrames de origem quilosa. Entretanto, alguns pontos, tais como a dose ideal, a duração do tratamento e os efeitos adversos em longo prazo, ainda precisam ser esclarecidos para que os inibidores de mTOR possam ser incorporados na abordagem da LAM. .

Avaliação do impacto de um programa de reabilitação pulmonar na capacidade de exercício em portadoras de linfangioleiomiomatose

Introdução: A linfangioleiomiomatose (LAM) é uma neoplasia de baixo grau, frequentemente associada à redução na capacidade de exercício, secundária a múltiplos fatores incluindo alteração de troca gasosa, limitação ventilatória e hiperinsuflação dinâmica (HD). A reabilitação pulmonar (RP) tem benefícios bem estabelecidos em diversas doenças pulmonares crônicas, porém não foi estudada na LAM. Objetivos: Avaliar o impacto de um programa de RP, comparativamente a um grupo controle, em portadoras de LAM, nos seguintes parâmetros: capacidade de exercício (objetivo primário), HD, dispneia, nível de atividade física diária, qualidade de vida, ansiedade e depressão, função pulmonar e força muscular. Metodologia: Ensaio clínico, controlado, não-randomizado, incluindo 21 pacientes com LAM no grupo RP e 19 no grupo controle. A RP teve duração de 3 meses, compreendendo 24 sessões de uma hora de duração (30 minutos de exercício aeróbico e 30 minutos de treinamento de força muscular). A avaliação inicial incluiu um teste de exercício cardiopulmonar (TECP) máximo incremental. As seguintes variáveis foram avaliadas antes e após a RP ou observação (grupo controle): capacidade de exercício, através do tempo até o limite da tolerância (Tlim) no teste de exercício cardiopulmonar (TECP) com carga constante; distância percorrida e dessaturação de oxigênio no teste de caminhada de 6 minutos (TC6M); dispneia (escala de dispneia do Medical Research Council modificada - mMRC, Índice de Dispneia Basal - BDI, e Índice Transicional de Dispneia - TDI); nível de atividade física diária (pedômetro); qualidade de vida relacionada à saúde (Questionário Respiratório de St George's, SGRQ); ansiedade e depressão (Escala Hospitalar de Ansiedade e Depressão, HADS); provas de função pulmonar (PFP) e força muscular (uma repetição máxima, 1 RM)...

Introduction: Lymphangioleiomyomatosis (LAM) is a low-grade neoplasm, which is frequently associated with reduced exercise capacity, secondary to multiple factors including gas exchange impairment, ventilatory limitation and dynamic hyperinflation (DH). Pulmonary rehabilitation (PR) has proven benefits in many chronic pulmonary diseases but it was not evaluated in LAM. Objectives: To evaluate the impact of a PR program in women with LAM, when compared to a control group, in the following parameters: exercise capacity (primary outcome), DH, dyspnea, daily physical activity, quality of life, anxiety and depression, lung function and muscle strength. Methods: A non-randomized controlled clinical trial that included 21 LAM patients in the PR group and 19 in the control group. The PR program lasted 3 months, comprising 24 sessions of 1 hour (30 minutes of aerobic exercise and 30 minutes of muscle strength training). The initial evaluation included a maximum incremental cardiopulmonary exercise test (CPET). The following variables were assessed before and after PR or observation (control group): exercise capacity using the tolerable limit duration (Tlim) in constant work rate (CWR) exercise testing; walking distance and oxygen desaturation (six-minute walk test, 6MWT), dyspnea (Modified Medical Research Council Dyspnea Scale -mMRC; Basal Dyspnea Index - BDI, and Transitional Dyspnea Index -TDI); daily physical activity (pedometer); health-related quality of life (St George's Respiratory Questionnaire, SGRQ); anxiety and depression (Hospital Anxiety and Depression Scale, HADS); pulmonary function tests (PFT) and muscle strength (one-repetition maximum, 1RM)...

Doxiciclina em pacientes com linfangioleiomiomatose: biomarcadores e resposta funcional pulmonar / Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response

OBJETIVO: Avaliar o bloqueio da metaloproteinase da matriz (MMP)-2 e da MMP-9 e a variação do VEF1 em pacientes com linfangioleiomiomatose (LAM) após o uso de doxiciclina, um conhecido inibidor de MMP, durante 12 meses. MÉTODOS: Ensaio clínico aberto de braço único no qual as pacientes com diagnóstico de LAM receberam doxiciclina (100 mg/dia) durante 12 meses. Elas foram submetidas a prova de função pulmonar completa, teste de caminhada de seis minutos, avaliação da qualidade de vida e coleta de amostras séricas e urinárias para dosagem de MMP-2, MMP-9 e VEGF-D antes do início do tratamento com doxiciclina e após 6 e 12 meses de tratamento. RESULTADOS: Trinta e uma pacientes com LAM receberam doxiciclina durante 12 meses. Embora tenha havido um bloqueio efetivo da MMP-9 urinária e da MMP-2 sérica após o tratamento, os níveis séricos de MMP-9 e VEGF-D permaneceram estáveis. Com base na resposta à doxiciclina (determinada pela variação do VEF1), as pacientes foram divididas em dois grupos: respondedoras (doxi-R; n = 13) e não respondedoras (doxi-NR; n = 18). As pacientes com alterações espirométricas leves apresentaram melhor resposta à doxiciclina. Os efeitos colaterais mais comuns foram epigastralgia, náusea e diarreia, todos de leve intensidade. CONCLUSÕES: Em pacientes com LAM, o tratamento com doxiciclina resulta em um bloqueio eficaz das MMP, além de melhorar a função pulmonar e a qualidade de vida daqueles com doença menos grave. No entanto, esses benefícios não parecem estar relacionados ao bloqueio das MMP, o que sugere um mecanismo de ação diferente. (Registro Brasileiro de Ensaios Clínicos - ReBEC; número de identificação RBR-6g8yz9 [http://www.ensaiosclinicos.gov.br]).

OBJECTIVE: To assess blockade of matrix metalloproteinase (MMP)-2 and MMP-9, as well as the variation in FEV1, in patients with lymphangioleiomyomatosis (LAM) treated with doxycycline (a known MMP inhibitor) for 12 months. METHODS: An open-label, single-arm, interventional clinical trial in which LAM patients received doxycycline (100 mg/day) for 12 months. Patients underwent full pulmonary function testing, a six-minute walk test, and quality of life assessment, as well as blood and urine sampling for quantification of MMP-2, MMP-9, and VEGF-D levels-at baseline, as well as at 6 and 12 months after the initiation of doxycycline. RESULTS: Thirty-one LAM patients received doxycycline for 12 months. Although there was effective blockade of urinary MMP-9 and serum MMP-2 after treatment, there were no significant differences between pre- and post-doxycycline serum levels of MMP-9 and VEGF-D. On the basis of their response to doxycycline (as determined by the variation in FEV1), the patients were divided into two groups: the doxycycline-responder (doxy-R) group (n = 13); and the doxycycline-nonresponder (doxy-NR) group (n = 18). The patients with mild spirometric abnormalities responded better to doxycycline. The most common side effects were mild epigastric pain, nausea, and diarrhea. CONCLUSIONS: In patients with LAM, doxycycline treatment results in effective MMP blockade, as well as in improved lung function and quality of life in those with less severe disease. However, these benefits do not seem to be related to the MMP blockade, raising the hypothesis that there is a different mechanism of action. (Brazilian Registry of Clinical Trials - ReBEC; identification number RBR-6g8yz9 [http://www.ensaiosclinicos.gov.br]).

Linfangioleiomiomatose: relato de caso / Lymphangioleiomyomatosis: case report

A Linfangioleiomiomatose (LAM) é uma doença sistêmica rara, de etiologia desconhecida, que afeta quase exclusivamente mulheres em idade reprodutiva. Caracterizada pela proliferação atípica de células musculares lisas em diversos órgãos, especialmente pulmão, que leva ao desenvolvimento de um distúrbio ventilatório obstrutivo, de caráter progressivo, com hiperinsuflação pulmonar e diminuição da difusão de monóxido de carbono, devido aos inúmeros cistos que formados no parênquima pulmonar. A manifestação clínica mais comumé o pneumotórax. O fator hormonal tem sido exposto como coadjuvante no desenvolvimento da doença, já que esta atinge quase que exclusivamente indivíduos do sexo feminino e se intensifica durante a gestação. Pesquisas recentes verificaram ao corrência de mutações genéticas e presença de lesões que estão associadas à doença Esclerose Tuberosa; porém, há necessidadede mais estudos para afirmar essa correlação. O presente relatorefere-se a paciente do sexo feminino, 45 anos de idade, brasileira,leucoderma, com diagnóstico de Linfangioleiomiomatose que compareceu ao ambulatório de Odontologia do Instituto do Coração do Hospital das Clínicas (FMUSP), encaminhada pelo Departamento de Pneumologia, para avaliação odontológica pré-operatória de transplante pulmonar. Paciente contactuante,com dispneia e uso contínuo de cateter de oxigênio, apresentando em cadeira de rodas para mínimo esforço físico. Higiene oral insatisfatória evidenciada pela presença de tártaro, raiz residual inaproveitável e lesões cariosas. Sabe-se que a infecção está entre as maiores causas de perda do órgão recebido pelo transplantado e, por isso, a atuação do cirurgião-dentista é de suma importância para prevenir quadros sistêmicos infecciosos decorrentes de focos bucais, pré e pós-transplante.

The Lymphangioleiomyomatosis (LAM) is a rare systemic disease of unknown etiology that affects mainly women atreproductive age. Characterized by an atypical proliferation of smooth muscle cells in various organs, especially in thelungs, which leads to the development of obstructive lung disease, a progressive character, with hyperinflation anddecreased lung diffusion of carbon monoxide due to the numerous cysts that are formed in the lung parenchyma.The most common clinical manifestation is pneumothorax. The hormonal factor has been exposed as an adjuvant in thedevelopment of the disease since it affects almost exclusively women and intensifies during pregnancy. Recent researches verified the occurrence of mutations and genetic lesions thatare associated with the disease Tuberous Sclerosis, but further studies are necessary in order to affirm this correlation. This report refers to a female patient, 45 years of age, Brazilian, leukoderma, diagnosed with Lymphangioleiomyomatosis who attended the outpatient clinic of Dentistry from the Heart Institute, Hospital das Clínicas (FMUSP) forwarded by the Department of Pulmonology, for a lung transplantpreoperative dental evaluation. Patient with dyspnea and continuous use of oxygen catheter, performing in a wheelchair for minimal physical effort. Poor oral hygiene evidenced by the presence of tartar, root caries and residual unusable. It is known that infection is among the biggest causes of loss of the transplanted organ by the receiver and, therefore, the role of the dentist is very important to prevent systemic frameworks infectious foci resulting from oral pre-andpost-transplant.

Avaliação de hiperinsuflação dinâmica em pacientes com linfangioleiomiomatose através de teste de exercício cardiopulmonar e verificação da resposta à broncodilatação / Evaluation of dynamic hyperinflation in patients with lymphangioleiomyomatosis with cardiopulmonary exercise testing and verification of the response to bronchodilator

INTRODUÇÃO: Linfangioleiomiomatose (LAM) é uma doença rara, caracterizada pela proliferação de células musculares lisas atípicas ao redor de vias aéreas, vasos sanguíneos e linfáticos, com formação de cistos pulmonares difusos. Na prova de função pulmonar (PFP), a doença se caracteriza por padrão obstrutivo, aprisionamento aéreo e redução da capacidade de difusão do monóxido de carbono (DLCO), podendo haver resposta positiva ao teste de broncodilatação. No teste de exercício cardiopulmonar (TECP), a menor tolerância ao esforço é frequente e secundária a múltiplas causas, com maior destaque para a limitação ventilatória. Entretanto, nem todos os fatores potencialmente limitantes foram investigados. Os principais objetivos do estudo foram avaliar a prevalência e os preditores de hiperinsuflação dinâmica (HD) em pacientes com LAM, em comparação a mulheres saudáveis (controles), investigando-se adicionalmente a resposta ao broncodilatador. METODOLOGIA: Realizou-se avaliação transversal de 42 pacientes com LAM utilizando-se questionário de qualidade de vida, PFP e TECP incremental no ciclo-ergômetro, com medida seriada da capacidade inspiratória (CI) para definir HD, comparando-se aos controles. As pacientes foram ainda submetidas ao teste de caminhada de seis minutos (TC6M). A seguir, elas foram incluídas em uma avaliação randomizada, cruzada, placebocontrolada, duplo-cega (salbutamol inalatório vs. placebo). PFP e TECP com carga constante, com medida seriada da CI, foram realizadas após cada intervenção. RESULTADOS: Comparando-se aos controles, as pacientes com LAM apresentaram pior qualidade de vida, principalmente nos domínios físico e emocional, e padrão obstrutivo, aprisionamento aéreo e redução da DLCO na PFP. As pacientes demonstraram ainda menor capacidade de exercício, associada com limitação ventilatória, dispneia mais intensa e maior dessaturação no esforço. HD ocorreu em 55% das pacientes, mesmo naquelas com alteração funcional leve, e não foi...

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare disease that is characterized by the proliferation of atypical smooth muscle cells around the airways, blood vessels and lymphatics, with diffuse pulmonary cyst formation. An obstructive pattern, with air trapping, and a reduction in the diffusion capacity of the lungs for carbon monoxide (DLCO) are found in pulmonary function tests (PFTs), and there may be a positive response to the bronchodilation test. In the cardiopulmonary exercise testing (CPET), a lower exercise tolerance is frequent, secondary to multiple causes, with a greater emphasis on ventilatory limitation. However, not all potentially exercise limiting factors were evaluated. The aims of this study were to evaluate the prevalence and predictors of dynamic hyperinflation (DH) in patients with LAM in comparison with healthy women. The response to bronchodilator was also evaluated. METHODS: A cross-sectional study with 42 patients with LAM was conducted, with evaluation of a quality of life questionnaire, PFTs and a ramp CPET on cycle, with serial measurements of inspiratory capacity (IC) to establish DH. Data were compared with the healthy control subjects. The patients also performed the six-minute walk test (6MWT). Then, the patients were included in a randomized, placebo-controlled, doubleblind, crossover evaluation (inhaled salbutamol vs. placebo). After each intervention, they performed PFTs and endurance CPET with serial measurements of IC. RESULTS: In comparison with the healthy individuals, the patients with LAM experienced an impaired quality of life, mainly in the physical and emotional domains. They also had obstructive pattern, air trapping and lower DLCO in the PFTs. LAM was associated with diminished exercise performance, in association with ventilatory limitation, greater dyspnea intensity and exercise desaturation. DH occurred at a higher prevalence (55%) in patients with LAM, even in those with mild spirometric...

Doxiciclina em pacientes com linfangioleiomiomatose: segurança e eficácia no bloqueio de metaloproteinases / Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade

OBJETIVO: A linfangioleiomiomatose (LAM) é caracterizada pela presença de cistos pulmonares, cuja formação está associada à hiperreatividade de metaloproteinases de matriz (MMP), principalmente MMP-2 e MMP-9. Objetivamos comparar os níveis dessas MMPs entre pacientes com LAM e controles saudáveis, assim como avaliar, nas pacientes com LAM, a segurança e a eficácia do tratamento com doxiciclina, um potente inibidor de MMPs. MÉTODOS: Estudo clínico prospectivo no qual as pacientes com LAM receberam doxiciclina (100 mg/dia) por seis meses, coletando-se amostras de urina e sangue para a dosagem de MMP-2 e MMP-9 antes e ao final do período. Foram ainda obtidas amostras de 10 mulheres saudáveis. RESULTADOS: De 41 pacientes com LAM que iniciaram o tratamento, 34 concluíram o protocolo. Os níveis de MMP-9 sérica e urinária foram significativamente inferiores no grupo controle (p < 0,0001). Comparando-se os valores antes e após o tratamento, a mediana do nível sérico da MMP-9 reduziu de 919 ng/mL para 871 ng/mL (p = 0,05), enquanto a mediana da dosagem urinária de MMP-9 diminui de 11.558 pg/mL para 7.315 pg/mL (p = 0,10). A mediana da MMP-2 sérica apresentou um decréscimo significativo após o tratamento (p = 0,04). Não foram detectados níveis de MMP-2 urinária. Epigastralgia, náuseas e diarreia foram os efeitos adversos mais prevalentes, e geralmente autolimitados. Apenas 1 paciente interrompeu o tratamento devido a efeitos colaterais. CONCLUSÕES: Pela primeira vez, conseguiu-se evidenciar em pacientes com LAM a redução dos níveis séricos e urinários de MMPs após o uso de doxiciclina, que se mostrou uma medicação segura, com efeitos colaterais leves e toleráveis.

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is characterized by lung cysts, whose development is associated with matrix metalloproteinase (MMP) hyperactivity, principally that of MMP-2 and MMP-9. Our objective was to compare LAM patients and controls in terms of the levels of these MMPs, as well as to determine the safety and efficacy of treatment with doxycycline, a potent MMP inhibitor. METHODS: Prospective clinical study involving female LAM patients who received doxycycline (100 mg/day) for six months. Urine and blood samples were collected for the quantification of MMP-2 and MMP-9 before and after the treatment period. Samples from 10 healthy women were also collected. RESULTS:Of the 41 LAM patients who started the treatment, 34 completed the protocol. Serum and urinary MMP-9 levels were significantly lower in the controls than in the LAM patients (p < 0.0001). Comparing pre- and post-treatment values, we found that the median level of MMP-9 in serum decreased from 919 ng/mL to 871 ng/mL (p = 0.05), whereas that of MMP-9 in urine decreased from 11,558 pg/mL to 7,315 pg/mL (p = 0.10). After treatment, the median level of MMP-2 in serum was significantly lower (p = 0.04) and urinary MMP-2 levels were undetectable. Nausea, diarrhea, and epigastric pain were the most prevalent adverse affects and were often self-limiting. There was only one case in which the patient discontinued the treatment because of side effects. CONCLUSIONS: We have demonstrated, for the first time, a decrease in serum and urine levels of MMPs in LAM patients treated with doxycycline, which proved to be a safe medication, with mild and well-tolerated side effects.